

**Amendments to the claims:**

Claim 1-33 (Cancelled)

34. (New) A pharmaceutical composition adapted for oral administration comprising: ✓  
a) a per unit dose of 10, 12.5, 15, 20, 25, 30 or 40 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and  $539 \pm 4$   $\text{cm}^{-1}$ ;  
b) a disintegrant; and  
c) further pharmaceutically acceptable excipients.
35. (New) A composition according to claim 34 in which the disintegrant is sodium starch glycollate.
36. (New) A composition according to claim 35 in which the carrier further comprises dicalcium phosphate.
37. (New) A composition according to claim 36 in which the carrier further comprises magnesium stearate.
38. (New) A composition according to claim 37 which is in the form of a tablet or capsule.
39. (New) A pharmaceutical composition adapted for oral administration comprising: ✓  
a) a per unit dose of 10 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and  $539 \text{ cm}^{-1}$ ;  
b) a disintegrant, which is sodium starch glycollate; and  
c) further pharmaceutically acceptable excipients.
40. (New) A composition according to claim 39 in which the pharmaceutically acceptable excipients comprise dicalcium phosphate and magnesium stearate.
41. (New) A dosage unit according to claim 40, in tablet form, in which:  
a) the disintegrant consist of about 2.98 mg of sodium starch glycollate; and  
b) the pharmaceutically acceptable excipients comprise about 158.88 mg of dicalcium phosphate and about 1.75 mg of magnesium stearate.

42. (New) A pharmaceutical composition adapted for oral administration comprising: C
- a) a per unit dose of 20 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539  $\text{cm}^{-1}$ ;
  - b) a disintegrant, which is sodium starch glycollate; and
  - c) further pharmaceutically acceptable excipients.
43. (New) A composition according to claim 42 in which the pharmaceutically acceptable excipients comprise dicalcium phosphate and magnesium stearate.
44. (New) A dosage unit according to claim 43, in tablet form, in which:
- a) the disintegrant consist of about 5.95 mg of sodium starch glycollate; and
  - b) the pharmaceutically acceptable excipients comprise about 317.75 mg of dicalcium phosphate and about 3.50 mg of magnesium stearate.
45. (New) A pharmaceutical composition adapted for oral administration comprising: /
- a) a per unit dose of 30 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539  $\text{cm}^{-1}$ ;
  - b) a disintegrant, which is sodium starch glycollate; and
  - c) further pharmaceutically acceptable excipients.
46. (New) A composition according to claim 45 in which the pharmaceutically acceptable excipients comprise dicalcium phosphate and magnesium stearate.
47. (New) A dosage unit according to claim 46, in tablet form, in which:
- a) the disintegrant consist of about 8.93 mg of sodium starch glycollate; and
  - b) the pharmaceutically acceptable excipients comprise about 476.63 mg of dicalcium phosphate and about 5.25 mg of magnesium stearate.
48. (New) A pharmaceutical composition adapted for oral administration /  
comprising:
- a) a per unit dose of 40 mg, calculated on a free base basis, of paroxetine methanesulfonate in crystalline form and having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539  $\text{cm}^{-1}$ ;
  - b) a disintegrant, which is sodium starch glycollate; and
  - c) further pharmaceutically acceptable excipients.